vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and T1 Energy Inc. (TE). Click either name above to swap in a different company.
T1 Energy Inc. is the larger business by last-quarter revenue ($210.5M vs $139.2M, roughly 1.5× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -62.0%, a 97.5% gap on every dollar of revenue. T1 Energy Inc. produced more free cash flow last quarter ($55.0M vs $34.6M).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Sony Energy Devices Corporation , is a Japanese multinational company specializing in a variety of areas in the energy industry, and is a wholly owned subsidiary and part of the Devices Group of Sony. The company was established in February 1975 in Fukushima, Japan.
ADMA vs TE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $210.5M |
| Net Profit | $49.4M | $-130.6M |
| Gross Margin | 63.8% | 10.0% |
| Operating Margin | 45.1% | -45.0% |
| Net Margin | 35.5% | -62.0% |
| Revenue YoY | 18.4% | — |
| Net Profit YoY | -55.9% | -375.2% |
| EPS (diluted) | $0.20 | $-0.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | — | ||
| Q3 25 | $134.2M | $210.5M | ||
| Q2 25 | $122.0M | $132.8M | ||
| Q1 25 | $114.8M | $53.5M | ||
| Q4 24 | $117.5M | — | ||
| Q3 24 | $119.8M | $0 | ||
| Q2 24 | $107.2M | $0 | ||
| Q1 24 | $81.9M | $0 |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $-130.6M | ||
| Q2 25 | $34.2M | $-31.9M | ||
| Q1 25 | $26.9M | $-16.2M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $-27.5M | ||
| Q2 24 | $32.1M | $-27.0M | ||
| Q1 24 | $17.8M | $-28.5M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | 10.0% | ||
| Q2 25 | 55.1% | 24.7% | ||
| Q1 25 | 53.2% | 33.3% | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | — | ||
| Q3 25 | 38.0% | -45.0% | ||
| Q2 25 | 35.1% | -22.0% | ||
| Q1 25 | 30.4% | -44.2% | ||
| Q4 24 | 32.6% | — | ||
| Q3 24 | 33.1% | — | ||
| Q2 24 | 36.6% | — | ||
| Q1 24 | 26.7% | — |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | -62.0% | ||
| Q2 25 | 28.1% | -24.0% | ||
| Q1 25 | 23.4% | -30.4% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | — | ||
| Q2 24 | 29.9% | — | ||
| Q1 24 | 21.7% | — |
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.15 | $-0.87 | ||
| Q2 25 | $0.14 | $-0.21 | ||
| Q1 25 | $0.11 | $-0.11 | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.15 | $-0.20 | ||
| Q2 24 | $0.13 | $-0.19 | ||
| Q1 24 | $0.08 | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $34.1M |
| Total DebtLower is stronger | $72.1M | $547.3M |
| Stockholders' EquityBook value | $477.3M | $96.9M |
| Total Assets | $624.2M | $1.4B |
| Debt / EquityLower = less leverage | 0.15× | 5.65× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | $34.1M | ||
| Q2 25 | $90.3M | $8.5M | ||
| Q1 25 | $71.6M | $48.9M | ||
| Q4 24 | $103.1M | — | ||
| Q3 24 | $86.7M | $181.9M | ||
| Q2 24 | $88.2M | $219.6M | ||
| Q1 24 | $45.3M | $249.9M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | $547.3M | ||
| Q2 25 | — | $591.2M | ||
| Q1 25 | — | $603.2M | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $602.3M |
| Q4 25 | $477.3M | — | ||
| Q3 25 | $431.2M | $96.9M | ||
| Q2 25 | $398.3M | $183.9M | ||
| Q1 25 | $373.4M | $201.9M | ||
| Q4 24 | $349.0M | — | ||
| Q3 24 | $231.9M | $538.7M | ||
| Q2 24 | $188.3M | $561.6M | ||
| Q1 24 | $153.7M | $582.3M |
| Q4 25 | $624.2M | — | ||
| Q3 25 | $568.7M | $1.4B | ||
| Q2 25 | $558.4M | $1.4B | ||
| Q1 25 | $510.6M | $1.4B | ||
| Q4 24 | $488.7M | — | ||
| Q3 24 | $390.6M | $615.0M | ||
| Q2 24 | $376.4M | $644.4M | ||
| Q1 24 | $350.9M | $670.3M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | 5.65× | ||
| Q2 25 | — | 3.21× | ||
| Q1 25 | — | 2.99× | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.03× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $63.9M |
| Free Cash FlowOCF − Capex | $34.6M | $55.0M |
| FCF MarginFCF / Revenue | 24.8% | 26.1% |
| Capex IntensityCapex / Revenue | 0.8% | 4.2% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-42.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | — | ||
| Q3 25 | $13.3M | $63.9M | ||
| Q2 25 | $21.1M | $33.4M | ||
| Q1 25 | $-19.7M | $-44.8M | ||
| Q4 24 | $50.2M | — | ||
| Q3 24 | $25.0M | $-28.4M | ||
| Q2 24 | $45.6M | $-28.0M | ||
| Q1 24 | $-2.2M | $-16.2M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | $55.0M | ||
| Q2 25 | $18.7M | $10.6M | ||
| Q1 25 | $-24.4M | $-74.0M | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | $-34.0M | ||
| Q2 24 | $43.6M | $-35.6M | ||
| Q1 24 | $-4.6M | $-37.7M |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | 26.1% | ||
| Q2 25 | 15.3% | 8.0% | ||
| Q1 25 | -21.2% | -138.4% | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | 4.2% | ||
| Q2 25 | 2.0% | 17.2% | ||
| Q1 25 | 4.1% | 54.5% | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
TE
| Related Party | $120.1M | 57% |
| Nonrelated Party | $90.4M | 43% |
